W. Simonet

Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family.

T. Boone, Jane Guo, G. Senaldi, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

P. Kostenuik, D. Lacey, W. Dougall, 2012, Nature Reviews Drug Discovery.

Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis

H. Ke, W. S. Simonet, T. Wronski, 2018, Endocrinology.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

P. Kostenuik, S. Morony, D. Lacey, 2006, Bone.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

P. Kostenuik, M. Stolina, H. Ke, 2009, Bone.

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

P. Kostenuik, S. Morony, D. Lacey, 2000, The Journal of experimental medicine.

Generalized Degenerative Joint Disease in Osteoprotegerin (Opg) Null Mutant Mice

S. Morony, B. Bolon, W. S. Simonet, 2015, Veterinary pathology.